Company Filing History:
1 out of 3,687 
1 out of 1 Years Active: 2009
Title: Nathalie Sieben: Innovator in Ovarian Cancer Research
Introduction
Nathalie Sieben is a prominent inventor based in Maastricht, Netherlands. She has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of ovarian cancer. Her innovative work has led to the development of valuable diagnostic tools that can improve patient outcomes.
Latest Patents
Nathalie Sieben holds a patent for "Methylation markers for diagnosis and treatment of ovarian cancer." This patent includes twenty-three markers that are epigenetically silenced in ovarian cancers. These markers can be utilized diagnostically, prognostically, and therapeutically, allowing for tailored treatment options for individual patients. The restoration of expression of silenced genes can be therapeutically beneficial, especially if the silenced gene is a tumor-suppressor gene. Restoration can be achieved by supplying non-methylated copies of the silenced genes or polynucleotides encoding their products. Additionally, chemical demethylating agents or methylation inhibitors can be used for restoration. Kits for testing epigenetic silencing are also available for diagnostics, prognostics, or selecting personalized medicine treatments.
Career Highlights
Throughout her career, Nathalie Sieben has worked with esteemed institutions, including Johns Hopkins University and Oncomethylome Sciences, S.A. Her research has focused on the intersection of epigenetics and cancer, leading to groundbreaking advancements in the field.
Collaborations
Nathalie has collaborated with notable professionals in her field, including Wim Van Criekinge and Josef Straub. These collaborations have further enhanced her research and contributed to the development of innovative solutions in cancer treatment.
Conclusion
Nathalie Sieben's work in ovarian cancer research exemplifies the impact of innovation in medicine. Her patented methods and collaborative efforts continue to pave the way for advancements in personalized cancer treatment.